(19)
(11) EP 2 970 161 B8

(12) CORRECTED EUROPEAN PATENT SPECIFICATION
Note: Bibliography reflects the latest situation

(15) Correction information:
Corrected version no 1 (W1 B1)

(48) Corrigendum issued on:
17.10.2018 Bulletin 2018/42

(45) Mention of the grant of the patent:
15.08.2018 Bulletin 2018/33

(21) Application number: 14717540.0

(22) Date of filing: 07.03.2014
(51) International Patent Classification (IPC): 
C07D 275/00(2006.01)
C07D 417/04(2006.01)
A61K 31/381(2006.01)
A61P 3/04(2006.01)
 C07D 333/32(2006.01)
C07D 417/12(2006.01)
A61K 31/425(2006.01)
A61P 3/10(2006.01)
(86) International application number:
PCT/US2014/021732
(87) International publication number:
WO 2014/159054 (02.10.2014 Gazette 2014/40)

(54)

GPR120 AGONISTS FOR THE TREATMENT OF TYPE II DIABETES

GPR120-AGONISTEN ZUR BEHANDLUNG VON TYP-II-DIABETES

AGONISTES DE GPR120 POUR LE TRAITEMENT DU DIABÈTE DE TYPE 2

(84) Designated Contracting States:
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
Designated Extension States:
BA ME

(30) Priority: 14.03.2013 US 201361783213 P

(43) Date of publication of application:
20.01.2016 Bulletin 2016/03

(73) Proprietor: Janssen Pharmaceutica NV
2340 Beerse (BE)

(72) Inventors:
  • SUI, Zhihua
    Norristown, Pennsylvania 19403-1885 (US)
  • CAI, Chaozhong
    North Wales, Pennsylvania 19454 (US)
  • ZHANG, Xuqing
    Spring House, Pennsylvania 19477 (US)

(74) Representative: Carpmaels & Ransford LLP 
One Southampton Row
London WC1B 5HA
London WC1B 5HA (GB)


(56) References cited: : 
WO-A2-2010/048207
   
       
    Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).